Lupus anticoagulant hypoprothrombinemia syndrome: A case report [PDF]
Clinical Case Reports, 2023 Lupus anticoagulant hypoprothrombinemia syndrome (LAHPS) is a rare entity associated with an increased risk of hemorrhage. Corticosteroids have been used in its treatment with favorable results.
Natalia Acedo +5 more
doaj +2 more sources
Successful treatment of lupus anticoagulant hypoprothrombinemia syndrome with rituximab [PDF]
Thrombosis Journal, 2023 Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder secondary to development of antibodies against prothrombin protein, in the presence of antiphospholipid antibodies.
Sanober Nusrat +2 more
doaj +2 more sources
Clinical features and treatment of 70 children with lupus anticoagulant-hypoprothrombinemia syndrome: a retrospective study from a single center in China [PDF]
Research and Practice in Thrombosis and HaemostasisBackground: Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder characterized by the presence of lupus anticoagulant (LA) and acquired hypoprothrombinemia.
Dandan Tian +9 more
doaj +2 more sources
Lupus anticoagulant associated with low grade B-cell lymphoma and IgM paraproteinaemia with lupus cofactor phenomenon on DRVVT and SCT assays - a possible novel association [PDF]
Thrombosis JournalBackground Lupus anticoagulant (LA) is an in vitro phenomenon with prolongation of a phospholipid-dependent coagulation test which is not due to an inhibitor specific to a coagulation factor.
Ting Hon Stanford Li +4 more
doaj +2 more sources
Acquired hemophilia A in the setting of dual anticoagulation therapy and lupus anticoagulant: a case report [PDF]
Journal of Medical Case Reports, 2022 Background Acquired hemophilia A is a disorder caused by autoantibodies against coagulation factor VIII that may present with severe bleeding. We report a rare case of acquired hemophilia A presenting with coexisting lupus anticoagulant.
Victor Chen +4 more
doaj +2 more sources
Lupus anticoagulant in patients with COVID-19: A review [PDF]
Journal of Preventive Epidemiology, 2021 Introduction: Coronavirus disease 2019 (COVID-19) is characterized by a pro-coagulant state that can lead to fatal thromboembolic events. A high prevalence of lupus anticoagulant has been shown in several studies that may at least partially explain the ...
Milad Nazari Sabet +2 more
doaj +1 more source
Lupus anticoagulant-hypoprothrombinemia syndrome with severe bleeding diathesis after coronavirus disease 2019: a case report. [PDF]
Croat Med J, 2022 Brblić T +5 more
europepmc +3 more sources
Massive thrombosis and phlegmasia cerulea dolens while taking rivaroxaban: case report and review [PDF]
Jornal Vascular Brasileiro, 2021 Our study describes a fatal case of phlegmasia cerulea dolens and massive venous thrombosis in a patient taking rivaroxaban regularly to treat cerebral venous sinus thrombosis. Blood tests samples were positive for lupus anticoagulant.
Diego Chemello +6 more
doaj +1 more source
Lupus Science and Medicine, 2020 Objective Persistent positivity for lupus anticoagulant has been associated with an increased risk of thrombosis among patients with SLE. Persistent positivity is often defined as having two positive assessments separated by more than 90 days.
Laurence S Magder, Mertcan Avci
doaj +1 more source
Clinical and Applied Thrombosis/Hemostasis, 2021 On an international scale, guidelines and proposals for lupus anticoagulant detection have been published over the last 20 years, but until now, standardization has not been completely realized. The aim of this study was to evaluate the different ways of
Feng Lu +4 more
doaj +1 more source